Sunstone Therapies
Whole Person Healing. For All.
Rockville, United States · $8.5M raised
- Headquarters
- Rockville, Maryland
- Employees
- 11–50
- Business Model
- B2B2C
- Website
- sunstonetherapies.com
- Total Funding
- $8.5M
- Last Round
- $8.5M Venture RoundJan 2024
- Rounds
- 1
About
Sunstone Therapies is a medical facility and research organization establishing the gold standard for psychedelic-assisted therapy delivery within a medical framework. The company conducts FDA-approved clinical trials and operates purpose-built psychedelic therapy centers, with its flagship location — the Bill Richards Center for Healing — situated within a community cancer center in Rockville, Maryland. Sunstone's interdisciplinary team of oncologists, licensed mental health professionals, researchers, and clinical staff focuses on treating individuals with complex mental health challenges including cancer-related distress, PTSD, trauma, and depression. The company's mission is to make safe, effective psychedelic-assisted therapy accessible by developing standard-setting experiences, training and supporting therapists, and contributing to peer-reviewed research and national standards in psychedelic care.
Summary
Sunstone Therapies is a Biotech company based in Rockville, United States. It has raised $8.5M in total across 1 round, most recently a $8.5M Venture Round round in Jan 2024. Investors include Satori Capital, AlleyCorp and Lifeforce Capital.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2024
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...

Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...